UBS Group AG Purchases 165,211 Shares of Zura Bio Limited $ZURA

UBS Group AG increased its position in shares of Zura Bio Limited (NASDAQ:ZURA) by 54.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 470,540 shares of the company’s stock after acquiring an additional 165,211 shares during the quarter. UBS Group AG’s holdings in Zura Bio were worth $2,466,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Suvretta Capital Management LLC raised its stake in shares of Zura Bio by 12.6% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock worth $23,698,000 after acquiring an additional 611,952 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. Armistice Capital LLC raised its stake in shares of Zura Bio by 1.6% during the 3rd quarter. Armistice Capital LLC now owns 1,560,000 shares of the company’s stock worth $6,755,000 after acquiring an additional 24,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Zura Bio during the 3rd quarter worth approximately $3,568,000. Finally, Ameriprise Financial Inc. bought a new position in shares of Zura Bio during the 3rd quarter worth approximately $2,165,000. Institutional investors own 61.14% of the company’s stock.

Insider Activity at Zura Bio

In other Zura Bio news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were acquired at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the acquisition, the insider directly owned 6,552,725 shares of the company’s stock, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 22.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently commented on ZURA shares. Oppenheimer reduced their price objective on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Friday, March 20th. Chardan Capital boosted their target price on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Wedbush assumed coverage on shares of Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Price Performance

ZURA stock opened at $4.21 on Wednesday. The firm’s fifty day simple moving average is $5.33 and its 200-day simple moving average is $5.24. The company has a market capitalization of $399.45 million, a P/E ratio of -3.86 and a beta of 0.09. Zura Bio Limited has a 12 month low of $0.98 and a 12 month high of $7.44.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, sell-side analysts forecast that Zura Bio Limited will post -0.73 earnings per share for the current year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.